

Attorney Docket No. 60005161-0168

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED
CENTRAL FAX CENTER

In re Patent Application of:

Herbert W. Virgin

Application No. 10/757,832

Filed: January 14, 2004

For: MURINE CALICIVIRUS

) Group Art Unit: 1648

) Examiner: Stacy Brown Chen

DEC 22 2005

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
BEFORE MAILING DATE OF EITHER A FINAL ACTION
OR NOTICE OF ALLOWANCE (37 C.F.R. § 1.97(c))

SUBSTITUTE INFORMATION DISCLOSURE STATEMENT

The information disclosure statement transmitted herewith is being filed *after* three months of the filing date of this national application or the date of entry of the national stage as set forth in Section 1.491 in an international application or after the mailing date of the first Office action on the merits, whichever event occurred last but *before* the mailing date of either a final action under Section 1.113 or a notice of allowance under Section 1.311, whichever occurs first.

This information disclosure statement will replace the information disclosure statement filed on December 23, 2004, by former counsel for Applicant. A copy of cite number 7 is enclosed. Copies of the remaining references were provided to the Office on December 23, 2004.

12/23/2005 TL0111 00000004 10757832

01 FC:1006

100.00 0P

10/757,832 (60005161-0168)
Transmittal of Information Disclosure Statement
Page 2

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 C.F.R. § 1.97(g)), an admission that the information cited is, or is considered to be, material to patentability, or that no other material information exists.

The filing of this information disclosure statement shall not be construed as an admission against interest in any manner. Notice of January 9, 1992, 1135 O.G. 13-25, at 25.


Applicant submits a credit card payment form in the amount of \$180.00 to cover the fee set forth in 37 C.F.R. § 1.17(p) for submission of an information disclosure statement under § 1.97(c).

The Commissioner is hereby authorized to credit overpayments or to charge any deficiency in a required fee to Deposit Account No. 19-3140. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

Dated: December 22, 2005

By:


Saul L. Jackson, Ph.D.
Registration No. 52,391
SONNENSCHN NATH & ROSENTHAL
P.O. Box 061080
Wacker Drive Station, Scars Tower
Chicago, Illinois 60606-1080
(314) 259-5802

23188832\V-1

PTO/SB/08B (08-03)

Approved for use through 06/30/2008. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/757,632
				Filing Date	January 14, 2004
				First Named Inventor	Herbert W. Virgin
				Art Unit	1648
				Examiner Name	Stacy Brown Chen
(use as many sheets as necessary)				Attorney Docket Number	60005161-0168
Sheet	1	of	1		
OTHER ITEMS - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	1	BALL et al., "Oral Immunization with Recombinant Norwalk Virus-Like Particles Induces a Systemic and Mucosal Immune Response in Mice," J. Virol., 1998, pp. 1345-1353, Vol. 72.			
	2	GEISLER et al., "Feline Calicivirus Capsid Protein Expression and Capsid Assembly in Cultured Feline Cells," J. Virol., 1999, pp. 834-838, Vol. 73.			
	3	GREEN et al., "Comparison of the Reactivities of Baculovirus-Expressed Recombinant Norwalk Virus Capsid Antigen with Those of the Native Norwalk Virus Antigen in Serologic Assays and Some Epidemiologic Observations," J. Clin. Microbiol., 1993, pp. 2185-2191, Vol. 31.			
	4	GREEN et al., "Expression and Self-Assembly of Recombinant Capsid Protein from the Antigenically Distinct Hawaii Human Calivirus," J. Clin. Microbiol., 1997, pp. 1909-1914, Vol. 35.			
	5	GUERRERO et al., "Recombinant Norwalk Virus-Like Particles Administered Intranasally to Mice Induce Systemic and Mucosal (Fecal and Vaginal) Immune Responses," J. Virol., 2001, pp. 9713-9722, Vol. 75.			
	6	JIANG et al., "Baculovirus Expression and Antigenic Characterization of the Capsid Proteins of Three Norwalk-Like Virus," Archives of Virol., 2002, pp. 119-130, Vol. 147.			
	7	JIANG et al., "Expression, Self-Assembly, and Antigenicity of the Norwalk Virus Capsid Protein," J. Virol., 1992, pp. 6527-5532, Vol. 66.			
	8	LIANG et al., "Protection Against Fatal Sindbis Virus Encephalitis by Beclin, a Novel Bcl-2-Interacting Protein," J. Virol., 1998, pp. 8586-8696, Vol. 72.			
	9	PELOSI et al., "The Seroepidemiology of Genogroup 1 and Genogroup 2 Norwalk-Like Viruses in Italy," J. Med. Virol., 1999, pp. 93-99, Vol. 58.			
	10	PRASAD et al., "Structural Studies of Recombinant Norwalk Capsids," J. Infect. Dis., 2000, pp. S317-S321, Vol. 181.			
	11	WHITE et al., "Attachment and Entry of Recombinant Norwalk Virus Capsids to Cultured Human and Animal Cell Lines," J. Virol., 1996, pp. 6589-6597, Vol. 70.			
Examiner Signature				Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1540, Alexandria, VA 22113-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form call 1-800-PTO-0400 and select option 3.